Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
12
RYTM Quote, Financials, Valuation and Earnings
Last price:
$94.90
Seasonality move
:
-15.16%
Day range:
$90.84 - $97.81
52-week range:
$45.91 - $122.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.75x
P/B ratio:
44.50x
Volume:
1.3M
Avg. volume:
688.3K
1-year change:
74.96%
Market cap:
$6.2B
Revenue:
$189.8M
EPS (TTM):
-$3.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$56.2M | -$0.78 | 72.09% | -0.07% | $140.67 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
GERN
Geron Corp.
|
$50.4M | -$0.05 | 26.52% | -32.89% | $3.40 |
|
JNJ
Johnson & Johnson
|
$24.1B | $2.46 | 7.79% | -40.82% | $233.13 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 38.37% | 136.8% | $1,214.34 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 36.67% | -59.34% | $7.94 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$92.73 | $140.67 | $6.2B | -- | $0.00 | 0% | 31.75x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
GERN
Geron Corp.
|
$1.68 | $3.40 | $1.1B | -- | $0.00 | 0% | 6.09x |
|
JNJ
Johnson & Johnson
|
$248.43 | $233.13 | $598.7B | 22.49x | $1.30 | 2.09% | 6.40x |
|
LLY
Eli Lilly & Co.
|
$1,051.99 | $1,214.34 | $992.4B | 46.57x | $1.73 | 0.59% | 14.70x |
|
MNKD
MannKind Corp.
|
$3.28 | $7.94 | $1B | 195.24x | $0.00 | 0% | 2.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
63.61% | 0.368 | 3.4% | 3.92x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
GERN
Geron Corp.
|
-- | 0.298 | -- | 3.16x |
|
JNJ
Johnson & Johnson
|
37.69% | -0.034 | 9.9% | 0.69x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.251 | 4.56% | 0.71x |
|
MNKD
MannKind Corp.
|
112.08% | 0.597 | 27.19% | 1.23x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$52.5M | -$47.1M | -61.67% | -310.34% | -82.2% | -$26.3M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
GERN
Geron Corp.
|
$46.7M | -$10.8M | -18.85% | -33.5% | -22.47% | -$13.5M |
|
JNJ
Johnson & Johnson
|
$16.4B | $5.4B | 21.45% | 34.46% | 21.9% | $5.9B |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
Rhythm Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns RYTM or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 96.33%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About RYTM or ACAD?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $140.67, signalling upside risk potential of 52.77%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is RYTM or ACAD More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock RYTM or ACAD?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or ACAD?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.75x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.31.75x -- $57.3M -$47.5M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns RYTM or GERN?
Geron Corp. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -64.86%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat Geron Corp.'s return on equity of -33.5%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M GERNGeron Corp.97.28% -$0.05 $223.6M -
What do Analysts Say About RYTM or GERN?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $140.67, signalling upside risk potential of 52.77%. On the other hand Geron Corp. has an analysts' consensus of $3.40 which suggests that it could grow by 102.38%. Given that Geron Corp. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 GERNGeron Corp.3 1 1 -
Is RYTM or GERN More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.581, suggesting its less volatile than the S&P 500 by 41.892%.
-
Which is a Better Dividend Stock RYTM or GERN?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or GERN?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are larger than Geron Corp. quarterly revenues of $48M. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than Geron Corp.'s net income of -$31.1M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.75x versus 6.09x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.31.75x -- $57.3M -$47.5M GERNGeron Corp.6.09x -- $48M -$31.1M
-
Which has Higher Returns RYTM or JNJ?
Johnson & Johnson has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 20.83%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat Johnson & Johnson's return on equity of 34.46%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M JNJJohnson & Johnson66.77% $2.10 $130.9B -
What do Analysts Say About RYTM or JNJ?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $140.67, signalling upside risk potential of 52.77%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -6.41%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 JNJJohnson & Johnson9 10 0 -
Is RYTM or JNJ More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.
-
Which is a Better Dividend Stock RYTM or JNJ?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.09% to investors and pays a quarterly dividend of $1.30 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RYTM or JNJ?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than Johnson & Johnson's net income of $5.1B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.75x versus 6.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.31.75x -- $57.3M -$47.5M JNJJohnson & Johnson6.40x 22.49x $24.6B $5.1B
-
Which has Higher Returns RYTM or LLY?
Eli Lilly & Co. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 34.4%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About RYTM or LLY?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $140.67, signalling upside risk potential of 52.77%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 15.43%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 LLYEli Lilly & Co.18 6 0 -
Is RYTM or LLY More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.
-
Which is a Better Dividend Stock RYTM or LLY?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.73 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RYTM or LLY?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.75x versus 14.70x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.31.75x -- $57.3M -$47.5M LLYEli Lilly & Co.14.70x 46.57x $19.3B $6.6B
-
Which has Higher Returns RYTM or MNKD?
MannKind Corp. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -14.25%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About RYTM or MNKD?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $140.67, signalling upside risk potential of 52.77%. On the other hand MannKind Corp. has an analysts' consensus of $7.94 which suggests that it could grow by 159.15%. Given that MannKind Corp. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 MNKDMannKind Corp.8 1 0 -
Is RYTM or MNKD More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.
-
Which is a Better Dividend Stock RYTM or MNKD?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or MNKD?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than MannKind Corp. quarterly revenues of $112M. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than MannKind Corp.'s net income of -$15.9M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 195.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.75x versus 2.94x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.31.75x -- $57.3M -$47.5M MNKDMannKind Corp.2.94x 195.24x $112M -$15.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
